LYVE1 Recombinant Rabbit monoclonal Antibody IgG
Fig1: Western blot analysis of LYVE1 on MCF-7 lysates using anti-LYVE1 antibody at 1/1,000 dilution.
Fig2: ICC staining LYVE1 in A431 cells (red). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Fig3: ICC staining LYVE1 in HUVEC cells (red). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Host Species; Species ReactivityRabbit; Human, Mouse, Rat
Application SummaryWB, ICC/IF, IHC, FC
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesLymphatic vessel endothelial hyaluronic acid receptor 1, Cell surface retention sequence-binding protein 1, Extracellular link domain-containing protein 1, Hyaluronic acid receptor
BackgroundLymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) is expressed on the cell surface as a protein that is reduced by glycosidase treatment. LYVE-1 is abundant in spleen, lymph node, heart, lung and fetal liver, and is less abundant in appendix, bone marrow, placenta, muscle and adult liver. Expression of LYVE-1 is largely restricted to endothelial cells lining lymphatic vessels and splenic sinusoidal endothelial cells. LYVE-1 binds to both soluble and immobilized hyaluronan (HA) with greater specificity than HCAM. Like HCAM, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike HCAM, the LYVE-1 molecule co-localizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves. LYVE-1 is used as a marker to study tumor lymphangiogenesis, which is an important area of investigation.(ET1702-29)